Skip to main content

Advertisement

SpringerLink
Log in

Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine

  • ORIGINAL ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Percutaneous coronary intervention and anti-anginal medications have similar prognostic effectiveness in patients with chronic stable angina. The choice of optimal medical therapy for the management of chronic angina is of pivotal importance in patients with stable ischemic heart disease. The most commonly used anti-anginal agents have demonstrated equivalent efficacy in improving patient reported ischemic symptoms and quantitative exercise parameters. With regards to mortality, beta-blockers are beneficial only in the setting of depressed left ventricular systolic function after a recent myocardial infarction. Recent evidence suggests the lack of any benefit of beta-blockers in patients with preserved systolic function, even in the setting of prior myocardial infarction.

Ranolazine is a non-haemodynamic anti-anginal agent. It is effective as adjunctive therapy in patients with chronic stable angina whose symptoms are un-adequately controlled by conventional treatment. The clinical development program of ranolazine has shown that the drug improves exercise performance, decreases angina and use of sublingual nitrates, compared to placebo. Ranolazine is well tolerated with neutral effect on haemodynamics. Besides its role in chronic stable angina, ranolazine has the potential for development in a number of other cardiovascular and non-cardiovascular conditions in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.

  2. Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary heart disease statistics 2010. British Heart Foundation 2010.

  3. Rosano GM, Fini M, Caminiti G, Barbaro G. Cardiac metabolism in myocardial ischemia. Curr Pharm Des. 2008;14(25):2551–62.

    Article  CAS  PubMed  Google Scholar 

  4. Rosano GM, Collins P. Gender differences in treatment of cardiovascular disease: a task force on gender of the ESC proposal on gender specific studies in cardiovascular pharmacology. Fundam Clin Pharmacol. 2010;24(6):662–3.

    Article  CAS  PubMed  Google Scholar 

  5. Boden W, O‘Rourke R, Teo K, et al. Optimal medical therapy with or without PCI for stable coronary disease: the COURAGE trial. N Engl J Med. 2007;356:1503–16.

    Article  CAS  PubMed  Google Scholar 

  6. Summary of Product Characteristics. Ranexa® (ranolazine). http://www.medicines.org.uk/EMC/medicine/21402/SPC/Ranexa%20prolonged-release%20tablets/

  7. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004;6(suppl A):A13–7.

    Google Scholar 

  8. Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol. 1996;497:337–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992;71:1231–41.

    Article  CAS  PubMed  Google Scholar 

  10. Wu J, Corr PB. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Phys. 1994;266:H1034–46.

    CAS  Google Scholar 

  11. Ward CA, Giles WR. Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol. 1997;500:631–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Huang B, El Sherif T, Gidh-Jain M, et al. Alterations of sodium canne kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol. 2001;12:218–25.

    Article  CAS  PubMed  Google Scholar 

  13. Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ Res. 1991;68:1250–8.

    Article  CAS  PubMed  Google Scholar 

  14. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in Guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192–9.

    Article  CAS  PubMed  Google Scholar 

  15. Undrovinas AI, Undrovinas NA, Belardinelli L. Ranolazine inhibits late sodium current in isolated left ventricular myocytes of dogs with heart failure. J Am Coll Cardiol. 2004;43:178A.

    Article  Google Scholar 

  16. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fraser H, Belardinelli L, Wang L, et al. Inhibition of late INa by ranolazine reduces Ca2 overload and LV mechanical dysfunction in ejecting rat hearts. Eur Heart J. 2005;26(abstract suppl.):414.

    Google Scholar 

  18. Gralinski MR, Black SC, Kilgore KS, et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28:1231–7.

    Article  CAS  PubMed  Google Scholar 

  19. Maruyama K, Hara A, Hashizume H, et al. Ranolazine attenuates palmitoyl-L-carnitine induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol. 2000;52:709–15.

    Article  CAS  PubMed  Google Scholar 

  20. Chaitman BR, Skettino SL, Parker JO, Ramos H-VA, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–82.

    Article  CAS  PubMed  Google Scholar 

  21. Chaitman BR, Pepine CJ, Parker JO, for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA. 2004;291:309–16.

    Article  CAS  PubMed  Google Scholar 

  22. Stone PH, Gratsiansky NA, Blokhin A, Huang I-Z, Meng L, for the ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48:566–75.

    Article  CAS  PubMed  Google Scholar 

  23. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, for the MERLIN-TIMI 36 Trial Investigators, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 Randomized Trial. JAMA. 2007;297:1775–83.

    Article  CAS  PubMed  Google Scholar 

  24. Kosiborod M, Arnold SV, Spertus JA, et al. The TERISA study (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038–45.

    Article  CAS  PubMed  Google Scholar 

  25. Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016;133(1):39–47.

    Article  CAS  PubMed  Google Scholar 

  26. Savarese G, Rosano G, D’Amore C, et al. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. Int J Cardiol. 2013;169(4):262–70.

    Article  PubMed  Google Scholar 

  27. Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, Jochelson P, Belardinelli L, Henry RH. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016;18(5):463–74.

    Article  CAS  PubMed  Google Scholar 

  28. Hidalgo-Vega A, Ramos-Goñi JM, Villoro R. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Eur J Health Econ. 2013;15(9):917–25.

Download references

Author information

Authors and Affiliations

  1. Clinical Academic Group, St George’s Hospital NHS Trust, Cranmer Terrace, London, SW17 0RE, UK

    Giuseppe M. C. Rosano & Cristiana Vitale

  2. Cardiovascular and Cell Sciences Research Institute, St George’s University of London, Cranmer Terrace, London, SW17 0RE, UK

    Giuseppe M. C. Rosano, Cristiana Vitale & Maurizio Volterrani

  3. Department of Medical Sciences, IRCCS San Raffaele Roma, Via della Pisana, 235, 00163, Rome, Italy

    Giuseppe M. C. Rosano & Cristiana Vitale

Authors
  1. Giuseppe M. C. Rosano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristiana Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maurizio Volterrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe M. C. Rosano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosano, G.M.C., Vitale, C. & Volterrani, M. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine. Cardiovasc Drugs Ther 30, 393–398 (2016). https://doi.org/10.1007/s10557-016-6674-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-016-6674-1

Keywords

Search

Navigation